Jonathan Lockhart
Psychiatry · Longview, TXNPI 1679678403
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $693,844 of the $764,569 with a category attached, or 90.7%. AbbVie accounts for 92.8% of it on its own, with 32 other manufacturers making up the rest. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,784 payments — averaging $428.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$710K
- Eisai Inc.$27K
- E.r. Squibb & Sons, L.L.C.$10K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$5K
- Otsuka America Pharmaceutical, Inc.$3K
- Teva Pharmaceuticals USA, Inc.$2K
- plus $7K from 27 others
What the payments were for
- Consulting fees$1,7400%
- Speaking & faculty fees$693,84491%
- Travel & lodging$43,3326%
- Food & beverage$24,7323%
- Education$9210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$764,569 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 56 | $476,164 |
| VraylarCariprazine Hcl | 289 | $461,612 |
| Austedo XrDeutetrabenazine | 37 | $264,984 |
| AustedoDeutetrabenazine | 13 | $98,181 |
| RexultiBrexpiprazole | 32 | $47,103 |
| TrintellixVortioxetine Hydrobromide | 74 | $43,572 |
| BelsomraSuvorexant | 77 | $32,856 |
| LybalviOlanzapine/Samidorphan Malate | 19 | $32,543 |
| AuvelityDextromethorphan Hbr/Bupropion | 25 | $31,529 |
| Invega SustennaPaliperidone Palmitate | 13 | $29,138 |
| SecuadoAsenapine | 14 | $20,494 |
| NuedextaDextromethorphan Hbr/Quinidine | 13 | $19,205 |
| DayvigoLemborexant | 40 | $15,414 |
| Lurasidone Hcl | 124 | $10,435 |
| Jornay PmMethylphenidate Hcl | 13 | $6,064 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $437 | $476,16456 claims |
| AbbVieVraylar | $709,578 | $461,612289 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $2,261 | $363,16550 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $323 | $48,62287 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $3,032 | $47,10332 claims |
| MerckBelsomra | $127 | $32,85677 claims |
| Alkermes, Inc.Lybalvi | $1,058 | $32,54319 claims |
| Axsome Therapeutics, Inc.Auvelity | $525 | $31,52925 claims |
| Johnson & JohnsonInvega Sustenna | $330 | $29,13813 claims |
| Noven Pharmaceuticals, Inc.Secuado | $23 | $20,49414 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $45 | $19,20513 claims |
| Eisai Inc.Dayvigo | $27,291 | $15,41440 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Longview
- Rakesh JainLake Jackson$7.2M
- Arvinder Pal WaliaAustin$2.5M
- Suresh SureddiPlano$2.2M
- Martin GuerreroEl Paso$2M
- Marty BennettAddison$1.8M
- Matthew BramsHouston$1.5M
- Vikram MehraKaty$1.2M
- Joel HolinerDallas$948K
- Frank ChenHouston$941K
- Alice MaoHouston$850K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.